MAP2K7 and neoplasm: Administration of exogenous FGF1, but not EGF, reduced the inhibitory effect on ERK1/2 activation by MEK inhibitors and reduced the inhibition of tumor growth by the ER antagonist ICI 182780 in MCF-7 cells [65].